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Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions  
Paul C. Langley 
College of Pharmacy University of Minnesota 
 
Note: An earlier version of this paper was submitted to the AMCP in December 2015 as a response to their publication of a draft for 
public comment of Version 4 of the AMCP Format for Formulary Submissions. There was no response received from the AMCP. This 
earlier version is available from the author. 
 
Abstract 
The question of demarcation between normal science and pseudoscience is critical to the discovery of new facts. The core elements 
supporting progress in science are: (i) empirically evaluable coherent theories and (ii) the testing of hypotheses through 
experimentation or systematic observation. If modeled or simulation-based claims for cost-effectiveness are to be accepted as a 
credible input to health care decision making than they must conform to these standards. Claims should be testable, falsifiable and 
replicable.  If not then they are best seen as pseudoscience. This assessment of the latest version of the Academy of Managed Care 
Pharmacy (AMCP) Format for Formulary Submissions (Version 4.0; April 2016) concludes that, in their recommendations for cost-
effectiveness modeling, the proposed standards do not meet those of normal science. Rather, in common with previous versions of 
the AMCP Format, the modeling framework proposed not only puts to one side the issue of testable claims, but supports the 
modeling of imaginary worlds or thought experiments where claims are immune to falsification. In consequence, the payer or other 
recipient of a modeled or simulated claim that follows the AMCP Format has no idea, in the absence of observation or 
experimentation, whether the claim is right or even if it is wrong. The claims are potentially misleading, possibly harmful, but to an 
unknown extent.  They have no place in evidence-based medicine.  
 
 
Introduction 
In April 2016, the Academy of Managed Care Pharmacy 
(AMCP) launched version 4 of their Format for Formulary 
Submissions 1. The purpose of the Format is to provide a 
framework to support the submission of clinical and cost-
effectiveness claims to health care purchasers in their 
assessment of new and competing pharmaceutical products 
and devices. The Format ‘is designed to maintain a high 
standard of objectivity and credibility’ in the information 
provided to manufacturers and at the same time streamlines 
the process. The adoption of the Format is regarded as best 
practice for the formulary review process.  
 
Given the widespread acceptance of the Format a legitimate 
question is whether or not the standards proposed for 
modeled or simulation-based cost-effectiveness and cost-
utility claims are credible: do they meet the standards of 
normal science?  
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If a modeled cost-effectiveness claim is to meet the standards 
of normal science then it has to (i) involve the construction of 
an empirically evaluable coherent theory and (ii) facilitate the 
testing of hypotheses through experimentation or 
observation. These are standards that have been in place 
since the 17th century and demarcate science from 
pseudoscience; the demarcation between natural selection 
and intelligent design 2. More specifically:  Do the standards 
support the construction of testable claims for product 
impact, claims that have the potential to provide meaningful 
feedback to a formulary committee as part of ongoing 
disease area and therapeutic reviews? Are the claims 
presented capable not only of evaluation but of falsification? 
Is there are a potential for the claims to be re-evaluated and 
replicated in other target patient populations? Can the claims 
be generalizable? 
 
The purpose of this paper is to point to a fatal 
epistemological error in the AMCP Format, one that has 
characterized, not only all previous versions of the AMCP 
recommendations for formulary submissions but also, 
unfortunately, those considered exemplar formulary 
submission guidelines. These guidelines include those from 
the National Institute for Health and Care Excellence (NICE) in 
the UK, the Pharmaceutical Benefits Advisory Committee 
(PBAC) in Australia, PHARMAC in New Zealand, the Health 
Quality Information Authority (HQIA) in Ireland and the 
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Canadian Agency for Drugs and Technologies in Health 
(CADTH) 3  4  5  6  7. The error is that none of these guidelines 
meet the standards for ‘normal science’: they support the 
construction of modeled product claims for clinical and cost-
effectiveness that fail to generate testable and reproducible 
hypotheses for the anticipated impact of products in health 
care systems. It is not a question of generalizability; the 
absence of testable claims means they are not, by definition, 
generalizable. 
 
As such, these models or simulations are best considered as 
imaginary worlds or thought experiments. The recipient of 
the submission has no idea, in the absence of 
experimentation or observation, of whether the claims made 
are right or even if they are wrong. While the author(s) of the 
modeled claims may justify their construct on the grounds 
that it reflects their perception of reality, the claims have the 
potential to be misleading and even harmful, but to an 
unknown and unknowable extent. As such, they should be 
put to one sider both by manufacturers and health system 
decision makers. 
 
The Standards of Normal Science 
The requirement for testable hypotheses in the evaluation 
and provisional acceptance of claims made for products and 
devices is unexceptional. Since the 17th century it has been 
accepted that if a research agenda is to advance, if there is to 
be an accretion of knowledge, there has to be a process of 
discovering new facts. Indeed, as early as the 16th century 
Leonardo da Vinci (1452 – 1519) in notes that appeared 
posthumously in 1540 for his Treatise on Painting (published 
in 1641) clearly anticipated the standards for the scientific 
method which were widely embraced a century later in 
rejecting thought experiments that fail the test of experience. 
By the 1660s, the scientific method, following the seminal 
contributions of Bacon, Galileo, Huygens and Boyle, had been 
clearly articulated by associations such as the Academia del 
Cimento in Florence (1657) and the Royal Society in England 
(founded 1660; Royal Charter 1662) with their respective 
mottos Provando e Riprovando (prove and again prove) and 
nullius in verba (take no man’s word for it).  
 
In the early 20th century standards for empirical assessment 
were put on a sound methodological basis by Popper in his 
advocacy of a process of ‘conjecture and refutation 8  9.  
Hypotheses or claims must be capable of falsification; indeed 
they should be framed in such a way that makes falsification 
likely. Life becomes more interesting if claims are falsified 
because this forces us to reconsider our models and the 
assumptions built into those models. This leads, then, to the 
obvious point that claims or models should not be judged on 
the realism or reasonableness of assumptions or on whether 
the model ‘represents’ reality. It is worth reflecting on 
Popper’s critique of induction: ‘never in science are 
inferences drawn from mere observational experience to the 
prediction of future events’ 10. Or, to put it simply: not all 
swans are white. 
 
It is not as though the issue of testable claims has not been 
raised before. This dichotomy between predictive validation 
and claims that a model is ‘realistic’ and that its claims should 
be taken at face value were recognized some 10 years ago in 
the WellPoint formulary submission guidelines in their focus 
on an outcomes based formulary 11  12. The guidelines, first 
issued in 2005, were explicit as to the need for predictive 
claims as an input to regular and ongoing disease area and 
therapeutic class reviews. The guidelines were designed to 
set standards for new product submissions as well as 
submissions to support disease area and therapeutic class 
reviews. A requirement in new submissions was that claims 
for costs and outcomes should be in a form that allowed 
evaluation in the short term. Those making a submission 
were asked to submit a protocol that detailed how these 
claims were to be assessed and reported back to the 
formulary committee. In the context of a life cycle 
perspective on drug products, initial claims were seen as 
provisional and subject to ongoing reviews to capture the 
impact of new products through comparative assessments. 
Claims that could not be verified were to be rejected, to 
include modeled claims and simulations that failed to 
generate testable hypotheses. 
 
More recently, in a supplement to the Journal of Medical 
Economics (JME), the case was put forward that if claims for 
the impact of products and devices on costs and outcomes in 
health care systems are to be accepted then they should 
meet the standards expected in ‘normal science’ 13  14  15  16  17. 
The only acceptable modeled claims in formulary submissions 
are those that are testable in a timeframe relevant to the 
needs of a formulary committee. If claims do not meet this 
standard they should be rejected. The supplement, given the 
experience of modeled claims made to NICE and the current 
situation in the US and other developed economies, proposed 
a new research agenda that focused on the testable impact of 
products and devices on patient outcomes, resource 
utilization and the costs of health care delivery. Key elements 
in this proposed new research agenda were that formulary 
submissions claims should be evaluated and reported on in a 
timeframe that is meaningful to the committee. In practice, 
this would mean 2-3 years with results reported on as part of 
ongoing disease area and therapeutic reviews. To support 
this process the supplement recommends that formulary 
submissions be accompanied by a protocol detailing how the 
claims are to be evaluated and a short list of questions a 
formulary committee should ask of a manufacturer’s 
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submission. At the same time the supplement points to the 
ready availability of ‘big data’ to support claims evaluation. 
 
Finally, it is important to point out that there has been 
increasing concern expressed in the last few years over the 
ability to replicate claims from pivotal phase 3 clinical trials. 
As noted in a recent editorial in Nature, applicants to the 
National Institutes of Health (NIH) are now required ‘to 
explain the scientific premise behind their proposals and 
defend the quality of their experimental design’ 18. More 
recently, Camerer et al in their evaluation of laboratory 
experiments in economics find, of the 18 studies considered, 
an effect size in the same direction in only 11 replications 
with on average a replicated effect size of 66% of the original 
19. As the authors point out ‘the deepest trust in scientific 
knowledge comes from the ability to replicate empirical 
findings’, although rarely carried out in the social sciences. 
 
At the same time concern has been expressed over the 
practice of outcomes switching where, in the process of 
reviewing evidence for the initial primary and secondary 
outcomes targets detailed in the phase 3 protocol, the data 
are ‘reconfigured’ to capture more statistically acceptable 
endpoints 20. 
 
Given that indirect comparisons utilizing techniques such a 
network analysis are a key input to modeled or simulated 
claims for comparative cost-effectiveness, the lack of 
replication in a significant proportion of phase 3 trials and the 
presence of outcomes switching raises doubts as to whether 
or not these indirect clinical efficacy claims should be taken at 
face value. It would appear to be more appropriate to 
consider such claims as simply working hypotheses. While it is 
worth noting that the potential impact of non-replicability 
and outcomes switching are not considered in the latest 
Format in the reporting of clinical claims, these claims should 
be evaluated as part of any formulary submission. 
 
If it is difficult to replicate claims from phase 3 clinical trials, 
then it is impossible to replicate claims that are untestable. In 
the case of modeled or simulated claims that adhere to the 
standards suggested by the AMCP Format, it is not the 
question of replication in other target populations but of not 
having a replicable claim in the first place. It is difficult to see 
how the support for non-testable modeled outcomes squares 
with the claim by the AMCP that decision models can provide 
‘benchmarks against which the product’s future performance 
can be measured’. If is not, as the AMCP goes on to say, the 
concern that models may be perceived as ‘black boxes’, 
rather it is the concern that they may be ‘empty boxes’. 
 
 
 
Cost-Outcomes Standards in the 2016 AMCP Format 
The 2016 AMCP Format recommendations are not intended 
to specify methods for assessing clinical benefit, harms or 
economic impact. The proviso is that they should meet 
accepted standards of evidence based medicine and health 
technology assessment. There is, in addition, a strong 
recommendation that formulary submissions include 
evidence from comparative effectiveness research studies, 
although this evidence may not be available at new product 
launch. Manufacturers are expected to articulate a value 
argument to justify expected expenditures for the product ‘in 
the context of its anticipated effects on the clinical evidence, 
health outcomes, and the economic consequences for the 
healthcare system’. In respect of the economic benefits, 
there should be a summary in terms of (i) cost per unit; (ii) 
potential clinical benefits (including quality of life) and 
potential economic benefits (including savings or cost 
offsets).  
 
The AMCP Format sees the intent of economic modeling to 
‘quantify for the healthcare system the risk-benefit tradeoff 
of the product and its economic value’. Decision based cost 
effectiveness models are seen as both effective and central to 
the case made for the product. In model development, 
manufacturers are asked to consider recommendations 
published by the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR). The 
analytic framework recommends including clinical events, life 
expectancy and quality adjusted life years (QALYs) ‘with the 
latter two outcomes primarily relevant for lifetime analyses’. 
There is no prescription for the modeling framework with 
manufacturers free to choose between decision trees, 
Markov or cohort models and patient level or discrete event 
simulation models. The simplest feasible modeling approach 
is recommended. A payer perspective in modeling is 
recommended with a time horizon ‘appropriate to the 
disease being studied’. Multiple timeframes are 
recommended for chronic disease e.g., 5-year, 10-year and 
lifetime’ and adjusted for time preference. In presenting a 
base-case analysis expected clinical and economic outcomes 
are to be estimated for each strategy (model) together with 
incremental costs and effectiveness. Differences in the 
absolute risk of events are to be calculated and healthcare 
offsets vs. drug costs should be presented, as should clinical 
risk-benefit tradeoffs. 
 
Consensus in Modeled and Simulated Claims 
There is nothing in the AMCP Format Version 4 (and earlier 
versions) that addresses the question of the importance of 
meeting the standards of normal science in models or 
simulations to support comparative clinical and cost-
effectiveness claims. To accept the position taken in the 
AMCP Format is to accept a relativist position in the 
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philosophy of science. Rather than subscribing to the position 
that the standards of normal science are the only standards 
to apply in health care decisions, the relativist believes that 
all perspectives are equally valid 21. In their advocacy of the 
equivalence or symmetry principle health care decisions are 
to be understood sociologically. No one body of evidence is 
superior to another. Results of a simulation are on an equal 
basis with those of a RCT. For the relativist, the success of a 
scientific research program, in this case one built on models 
and simulations, rests not on its ability to generate new 
knowledge but on its ability to mobilize the support of the 
community. Basing decisions on models and simulations 
underpins the consensus view that evidence is constructed, 
never discovered. Instead of coming to grips with reality 
science is about rhetoric, persuasion and authority. Truth is 
consensus. 
 
If we accept the relativist opinion and argue that decisions in 
healthcare are most appropriately based on models and 
simulations then we have to address the possibility that 
simulations can fail. Simulations or models are accepted 
because in the consensus view, the view of the authorities in 
the discipline, the ability to capture the critical or similar 
features of the reality of a decision is all that is required. If 
the simulated input conditions and the simulated core 
mechanism correspond to reality, the sufficient condition 
character of the simulation assures us that the output is 
necessarily entailed and predictions must corresponded to 
reality 22. 
 
At the same time there is unlikely ever to be agreement on 
correspondence, sufficiency and necessary entailment. The 
flexibility allowed in constructing simulations means that 
simulations, by their nature, can always fail. Simulations can 
also be ‘tailored’ to generate the required endpoints. Rather 
than capturing the essence of a reality, the simulation 
captures the perception of the essence held by the authors of 
the simulation. Unless there is a process of independent 
assessment through experimentation or observation, there is 
no way in which the likelihood of failure can be judged. To 
argue that readers will compare one simulation with another 
and attempt to rebut competing simulated claims through a 
comparison of a model’s structure or its assumptions is 
unlikely to be a useful exercise unless this is linked to the 
empirical evaluation of competing claims. 
 
These conclusions hold irrespective of how much we attempt 
to build up the appearance of being scientifically rigorous in 
the validation of models and simulations. We can claim that 
they ‘adequately reflect reality’, we can apply deterministic 
and probabilistic sensitivity analyses, we can produce 
incremental cost effectiveness ratios (ICER) cloud diagrams, 
we can apply thresholds, we can argue for face and content 
validity and we can even introduce an analysis of the value of 
perfect information. Nevertheless, the fundamental objection 
still applies: if there are no testable predictions the simulation 
fails the standards of normal science.  
 
Quality Adjusted Life Years 
The AMCP Format recommends that clinical events, life 
expectancy and quality adjusted life years (QALYs) all be 
assessed in the cost-effectiveness analysis. The last two 
endpoints are seen as primarily relevant for lifetime analyses. 
Following the standards of the NICE reference case 
preference estimates are to be derived from either patients 
or the general population. As well as direct preference 
elicitation, six possible instruments are referenced. There is 
no recommendation for any individual instrument or any 
suggestion that cost-per-QALY thresholds could be usefully 
applied to QALY claims.  
 
While a QALY may be seen, as the AMCP notes, as a universal 
health outcomes measure there is no discussion of how a 
particular QALY instrument is chosen. Instruments vary in the 
number of health dimensions included, the number of levels 
captured within each dimension and their severity. They also 
differ in the populations surveyed to elicit preferences for 
health states, how the preference score is derived and how 
the preference data are translated into a preference score. 
There is no discussion over recent claims that the preferences 
expressed over hypothetical health states are inconsistent 
with the assumptions of multiattribute utility theory 23. 
 
The issue of the relevance of incremental cost-per-QALY 
claims to health care decision making is not addressed. Given 
the recommendation that modeled claims should track the 
course of a chronic disease, there is no discussion of how 
formulary committees should factor ‘discounted’ 
comparative lifetime cost-per-QALY claims’ intro their 
decision making. Lifetime (or long-term) QALY based claims 
are obviously not evaluable. As such they fail to meet 
accepted standards for credibility in normal science. Indeed, 
even if QALYS were put in an evaluable form (e.g., evaluable 
within a 2-year time frame), the fact is that no one ‘collects’ 
QALYS (with a choice of six flavors to choose from) as 
elements in administrative claims or electronic medical 
records.  If evaluable QALY claims are to be assessed then a 
prospective observational or experimental study would have 
to be underwritten and implemented. As this is a less than 
likely proposition, this creates a further barrier to assessing 
QALY claims (let alone linking such claims to future 
comparative effectiveness assessments). In short, health care 
systems are not interested in QALYs. Single payer systems 
may mandate QALY outcomes in modeled claims but, at least 
in the case of NICE, these support threshold pricing 
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negotiations where there is no intention of ever evaluating 
the claims.  
 
ISPOR and Normal Science 
In failing to recognize the standards of normal science, the 
AMCP is not alone. Looking back over the past decade or 
more ISPOR in its commitment to developing standards has 
emphasized the role of assumptions rather than hypotheses 
in model development. Certainly, the notion of validation has 
been addressed, but rather than emphasizing the 
fundamental role of prediction and testable hypotheses, this 
has been seen as a preferred, yet not essential element in 
validation 24  25  26. While establishing a degree of belief in a 
model, it may seem odd if that model is incapable of 
generating testable claims. The point is that predictive 
validation is not just one type of validation. Predictive 
validation (or assessment) stands alone; it is the only basis on 
which a model can be judged. The risk, for both 
manufacturers and health care decision makers, is that the 
modeling is seen as so inherently elegant that it supplants, as 
Ellis and Silk note, the need for data and testing 27.  
Unfortunately, this avoids the critical question: what 
potential observational evidence would persuade you that 
the theory is wrong and lead you to abandoning it? If there is 
none then it is not a scientific theory. 
 
Implications of Accepting the AMCP Format for Formulary 
Submissions 
It is unclear from the AMCP recommendations whether the 
results of modeled claims, the ‘anticipated effects’ are ever 
intended to be put in a form that is testable. Indeed, the 
authors of the AMCP Format appear unconcerned as to 
whether or not claims are put in a form that are testable or 
whether or not it is appropriate that they capable of being 
tested, let alone reproduced. There seems to be little if any 
concern that there should be feedback to a formulary 
committee from claims evaluation as part of ongoing disease 
area and therapeutic class reviews. Some of the language 
used could be interpreted to mean that concrete claims could 
be evaluated but there is nothing in the recommendations to 
distinguish modeled claims that are potentially testable and 
meet the standards of normal science from claims that are 
the outcomes of modeled imaginary worlds or thought 
experiments. Note, in particular, the recommendations that 
the modeled time horizon should be ‘appropriate to the 
disease being studied’ and that for chronic diseases this could 
extend to the patient’s life time.  
 
This failure to recognize and follow the standards of normal 
science will, inevitably, raise doubts as to credibility of the 
AMCP Format and its relevance for health care decision 
making.  As well, doubt will be cast on not only of a large 
number of pharmacoeconomic studies, but on global 
formulary guideline standards and the contribution of 
formulary submissions to product placement. A project is 
currently underway at the College of Pharmacy, University of 
Minnesota to evaluate the credibility of published cost-
effectiveness claims. To date, modeled cost-effectiveness 
claims published in two journals, PharmacoEconomics and 
the JME, have been assessed and the results published 28  29. 
Both of these reviews asked: (i) whether the model was 
capable of generating evaluable claims; (ii) whether the 
author(s) attempted to generate evaluable claims; (iii) 
whether the author(s) suggested how the claims might be 
evaluated; and (iV0 whether the author(s) cautioned readers 
as to the implications of generating non-evaluable claims for 
the credibility of the analysis? Of the 63 papers reviewed in 
the two publications, none met these requirements. 
 
Conclusions and Recommendations 
The 2016 AMCP Format (as in previous versions) suffers from 
a major and fatal epistemological error: it fails to support the 
standards of normal science. If, on the one hand, the authors 
of the format agree that this is a desirable standard to aim 
for, then the document needs to make this quite clear. If they 
take a relativist position then that is the end of the argument. 
If, on the other hand, the authors of the 2016 AMCP Format 
accept the need that in models and simulation for cost-
outcomes claims they need to subscribe to the standards of 
normal science then this is probably best achieved by stating 
quite equivocally that claims made for the impact of 
pharmaceutical products and devices should be framed to 
ensure (i) that they are capable of empirical evaluation and 
replication; and  (ii) that they should be capable of being 
evaluated in a relatively short period of time; a period 
consistent with the requirements of a formulary committee 
and as inputs to ongoing disease area and therapeutic class 
reviews. There is no middle ground.  
 
In either event, following the WellPoint guidelines and the 
recommendations of the JME supplement, the AMCP 
recommendations should include a requirement that an 
evaluation protocol accompany claims for product impact. 
The JME supplement has provided a possible framework 
linked to questions that a formulary committee should ask. 
Developing such a protocol should be relatively 
straightforward given the experience in the drafting of 
protocols to support randomized clinical trials (RCT) and 
observational studies in comparative effectiveness research. 
Unless otherwise agreed by the parties, the content of the 
protocol should remain confidential and the request for a 
protocol should be at the discretion of the payer. Unless 
otherwise agreed, the costs of implementing the validation 
protocol should be borne by the manufacturer.  
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The concerns raised in this assessment of the latest AMCP 
Format in respect of evaluable and replicable product claims 
have been addressed in the recently published University of 
Minnesota Social and Administrative Pharmacy Program 
Proposed Guidelines for Formulary Evaluations30. Unlike the 
latest AMCP Format these guidelines emphasize the need to 
conform to the standards of normal science in submitting 
comparative claims for new products. A key element in the 
guidelines is the role of a protocol to be submitted to detail 
how the claims are to be evaluated in a timeframe that is 
meaningful to a formulary committee.  The guidelines point 
to the responsibility of the manufacturer to underwrite 
claims for both clinical and cost-effectiveness outcomes, 
potentially linking these assessments to subsequent 
comparative effectiveness disease area and therapeutic class 
reviews over the lifetime of the product.  
 
In focusing on claims that are evaluable in the short-term, the 
emphasis in model building will likely move away from those 
models which attempt to capture the natural course of a 
disease and more abstract reference case approaches. Unless 
they can adapt to generating short-term testable claims, 
cohort and Markov and discrete event simulation models are 
likely to be supplanted by models that are based on RCTs or 
extrapolate from them in the short term. It is also likely that 
claims for product impact will be in more disaggregated 
terms with claims for short-term clinical outcomes and 
resource utilization supplanting broad-based ‘value claims’ 
for incremental cost-effectiveness. While this does not 
discount claims based on patient reported outcomes or 
quality of life, cost-per-QALY claims are unlikely to take 
center stage with reference case frameworks disappearing. 
This does not mean, however, that the re-drafted AMCP 
recommendations should discourage evaluable PRO and 
QALY claims.      
 
Whether the AMCP and the authors of the AMCP Format are 
prepared to accept these recommendations is an open 
question. Given how much has been invested over the past 
15 years by the AMCP and ISPOR in recommendations for 
modeling claims and standards respectively, the risk is that 
with this sunk intellectual capital, there will be a reluctance to 
accept that a change in direction is required. If this is the 
case, then it is incumbent upon the AMCP to justify how 
untestable claims generated by imaginary worlds contribute 
to effective formulary decision making in, for example, 
precision medicine and support the evidentiary standards 
being demanded by Federal government agencies such as the 
Centers for Medicare and Medicaid Services for quality 
outcomes and metrics 31. With the arguments presented 
here, subscribing to the standards of normal science to drive 
a new research agenda offers the only sound basis for 
evidence driven decision making and for new frameworks for 
generating claims. 
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